Clinical Trials Logo

Spinocerebellar Degenerations clinical trials

View clinical trials related to Spinocerebellar Degenerations.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06177626 Not yet recruiting - Clinical trials for Spinocerebellar Ataxias

Impact of Exercise on Eyeblink Conditioning in Spinocerebellar Ataxias

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The goal of this project is to evaluate how aerobic training impacts eyeblink conditioning as a proxy for cerebellar dependent motor learning. The newly developed smartphone application, iBlink, will be used to test participants at home in an effort to improve recruitment and increase the sample size of the study. The investigators hypothesize that aerobic training, but not balance training, will improve eyeblink conditioning in participants with spinocerebellar ataxias. The current study focuses on Aim 3 of this project.

NCT ID: NCT06152133 Not yet recruiting - Cerebellar Ataxia Clinical Trials

Telerehabilitation, Core Stability Exercises and Hereditary Ataxia (TRCore-ataxia)

TRCore-ataxia
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Hereditary ataxias (HA) are a heterogeneous group of degenerative diseases of the cerebellum, brain stem and spinal cord. People who suffer from AH, among other symptoms, present deficiencies in the stability of the trunk, which leads to an alteration in postural control, with a strongly influential factor in the loss of balance and gait disorders. Improving the functionality of these physical aspects can help reduce the rate of falls, increase autonomy and quality of life for people with HA. Evidence suggests that rehabilitation strategies based on core stability exercises (CSE) are effective in improving balance and postural control in several neurological diseases, such as stroke. However, there is little evidence with people with HA. In a previous study carried out by researchers of this project, in which an EEC exercise program was piloted at home, low adherence to treatment was perceived due to the little follow-up that was given to the participants. Therefore, including telerehabilitation in these programs would increase follow-up and could influence adherence.

NCT ID: NCT03660917 Not yet recruiting - SCA7 Clinical Trials

Riluzole in Patients With Spinocerebellar Ataxia Type 7

Start date: January 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Spinocerebellar ataxia type 7 (SCA7) belongs to the dominant forms of inherited cerebellar ataxias (CA), being one of the rarest form. SCA7 has no therapeutic options, so that the relentless course, the important visual deficit that accompanies CA, and the possibility of disease development in childhood are pressing unmet needs. The investigators published encouraging data on riluzole in inherited CA other than SCA7. These results prompted off-label use of riluzole in single cases of SCA7 in Italy and United States, suggesting possible efficacy of the drug in this condition.

NCT ID: NCT03378414 Not yet recruiting - Clinical trials for Spinocerebellar Ataxia Type 3

Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia

Start date: December 31, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is verify the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar Ataxia, and in addition, explore the possible mechanisms of UC-MSC therapy in Spinocerebellar Ataxia.